Key Drivers
- Strong liquidity
- Modest returns
- High operating spend
AIAI Summary
ONC's shift to a hybrid commercial‑biotech—anchored by Brukinsa as a ~$3.9B, high‑margin cash engine and positive FCF—meaningfully de‑risks dilution and funds aggressive R&D/M&A, recasting the stock as a growth‑pharma with event‑driven upside rather than a binary pipeline bet. Monitor FCF acceleration, SG&A guidance cadence, and imminent Phase III/FDA readouts (sonrotoclax, BTK degrader): successes would justify the rich multiples, while misses or slower Brukinsa uptake would likely produce sharp downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Modest returns
- •High operating spend
ONC has strong liquidity, conservative leverage and robust FCF but modest returns and heavy operating spend, while market valuation appears rich versus current profitability.
Price Behavior
Key Price Behavior Insights:
- •Below last month
- •Sharp retracement
- •High intraday range
Price is in a short-term downtrend—trading well below its last month average (~$309) after a sharp ~24% drop from late-February highs into the $275 area, with $275 acting as near-term support and $298–$305 as the key zone to reclaim for a rebound.
~24% decline from ~$369–$352 in late
Sentiment & News
Key News Insights:
- •Brukinsa growth
- •Guidance miss
- •Upcoming FDA catalysts
BeOne posted strong Q4 and FY2025 results led by 49% Brukinsa growth, tempered by a modest 2026 guidance miss but supported by near‑term FDA catalysts (Sonrotoclax, BTK degrader) and modest institutional trimming.
The results and product momentum keep upside potential tied to regulatory readouts, though near‑term valuation may be pressured by conservative guidance and portfolio rebalancing
Similar Companies in Healthcare
Other companies in the same sector with AI ratings